Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Direct and indirect effects of IFN-α2b in malignancy treatment: not only an archer but also an arrow
Fei Xiong, Qi Wang, Guanhua Wu, et al.
Biomarker Research (2022) Vol. 10, Iss. 1
Open Access | Times Cited: 21

Showing 21 citing articles:

Immunologic tumor microenvironment modulators for turning cold tumors hot
Gholamreza Khosravi, Samaneh Mostafavi, Sanaz Bastan, et al.
Cancer Communications (2024) Vol. 44, Iss. 5, pp. 521-553
Open Access | Times Cited: 61
Potential role of immunotherapy and targeted therapy in the treatment of cancer: A contemporary nursing practice
Hamad Ghaleb Dailah, Abdullah Abdu Hommdi, Mahdi Dafer Koriri, et al.
Heliyon (2024) Vol. 10, Iss. 2, pp. e24559-e24559
Open Access | Times Cited: 10
Metabolic diseases and interferon immune responses
Haiyan Zhou, Chunyan Liu, Yuerong Zhang, et al.
Deleted Journal (2025)
Open Access | Times Cited: 1
Hypoxia: syndicating triple negative breast cancer against various therapeutic regimens
Nityanand Srivastava, Salman Sadullah Usmani, Rajasekaran Subbarayan, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 22
Interferon stimulated gene 15 (ISG15) in cancer: An update
Hong-My Nguyen, Shreyas Gaikwad, Mariam Oladejo, et al.
Cancer Letters (2023) Vol. 556, pp. 216080-216080
Open Access | Times Cited: 17
Mechanism of action of nadofaragene firadenovec-vncg
Vikram M. Narayan, Joshua J. Meeks, Jørn S. Jakobsen, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 5
Pbx3-mediated suppression of type I interferon response contributes to leukemia progression driven by MLL-AF9
Li Tang, Meng‐Yao Lu, Yushen Du, et al.
Cancer Gene Therapy (2025)
Closed Access
Evaluation of the duration of new nasal drug interferon α-2b activity in an experimental model system
Natalia Bezdieniezhnykh, O Lykhova, G. I. Borshchevskіy, et al.
Virology Journal (2025) Vol. 22, Iss. 1
Open Access
Effect of anti-COVID-19 drugs on patients with cancer
Weicai Huang, Wenyu Liu, Tingting Yu, et al.
European Journal of Medicinal Chemistry (2024) Vol. 268, pp. 116214-116214
Open Access | Times Cited: 3
Therapeutic potential of marine peptides in malignant melanoma
Salman Ahmed, Waqas Alam, Khalaf F. Alsharif, et al.
Environmental Research (2023) Vol. 227, pp. 115771-115771
Closed Access | Times Cited: 7
Mechanism of action and treatment of type I interferon in hepatocellular carcinoma
Chunxiu Peng, Zhijian Ye, Ying Ju, et al.
Clinical & Translational Oncology (2023) Vol. 26, Iss. 2, pp. 326-337
Closed Access | Times Cited: 7
The Immunotherapeutic Role of Type I and III Interferons in Melanoma and Non-Melanoma Skin Cancers
Sydney Weir, Kailash KC, Shoaib Shoaib, et al.
Life (2023) Vol. 13, Iss. 6, pp. 1310-1310
Open Access | Times Cited: 6
Emerging roles of plasmacytoid dendritic cell crosstalk in tumor immunity
Leilei Yang, Songya Li, Liuhui Chen, et al.
Cancer Biology and Medicine (2023), pp. 1-20
Open Access | Times Cited: 6
Overview of anti-viral effects of probiotics via immune cells in pre-, mid- and post-SARS-CoV2 era
Osamu Kanauchi, Zhao Xuan Low, Kenta Jounai, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 5
Engineering interferons for cancer immunotherapy
Juhee Lim, Heung Kyu Lee
Biomedicine & Pharmacotherapy (2024) Vol. 179, pp. 117426-117426
Open Access
Expression of MxA in esophageal cancer cell lines can influence sensitivity to chemotherapeutic agents but this does not require apoptosis
Robert Michael Hayes, Tracey R. O’Donovan, Sharon L. McKenna
Cancer Medicine (2024) Vol. 13, Iss. 17
Open Access
Deciphering Structural Dynamics of Atherosclerosis Proteins: Insights from Crataegus oxyacantha Phytochemicals that Interceded Functional and Structural Changes in Targeted Atherosclerotic Proteins
Praveen Jeeva, A Muthusamy, K. Jayachandra
ACS Omega (2024) Vol. 9, Iss. 49, pp. 48159-48172
Closed Access
Enhancing cancer care with improved checkpoint inhibitors: a focus on PD-1/PD-L1.
A.S. Vickram, Saghya Infant Shofia, A. Saravanan, et al.
PubMed (2024) Vol. 23, pp. 1303-1326
Closed Access
Partial Inhibition of Epithelial-to-Mesenchymal Transition (EMT) Phenotypes by Placenta-Derived DBMSCs in Human Breast Cancer Cell Lines, In Vitro
Yasser Basmaeil, Abdullah Al Subayyil, Haya Bin Kulayb, et al.
Cells (2024) Vol. 13, Iss. 24, pp. 2131-2131
Open Access
Magnetic Relaxation Switching Assay Using IFNα-2b-Conjugated Superparamagnetic Nanoparticles for Anti-Interferon Antibody Detection
B. P. Nikolaev, L. Yakovleva, Viacheslav Fedorov, et al.
Biosensors (2023) Vol. 13, Iss. 6, pp. 624-624
Open Access | Times Cited: 1
Nadofaragene: a new era of precision medicine for bladder cancer
Maha Zehra, Tehreem Fatima, Areeba Hanif, et al.
Annals of Medicine and Surgery (2023) Vol. 86, Iss. 1, pp. 7-10
Open Access | Times Cited: 1
Page 1

Scroll to top